+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Uterine Fibroid Treatment Drugs Market Size, Share & Trends Analysis Report By Drug Class (GnRH Agonists, GnRH Antagonists), By Type (Submucosal Fibroids, Intramural Fibroids), By End-user, And Segment Forecasts, 2023 - 2030

  • PDF Icon

    Report

  • 130 Pages
  • May 2023
  • Region: Global
  • Grand View Research
  • ID: 5830863
Description Jump to:
The global uterine fibroid treatment drugs market size is expected to reach USD 3.91 billion by 2030, expanding at a CAGR of 10.2% from 2022 to 2030. The growth of the market is attributed to the rising prevalence of Uterine Fibroids (UF) and the increased effectiveness of novel drugs in reducing heavy menstrual bleeding in women. According to an article published on IntechOpen, heavy menstrual bleeding is a common symptom of uterine fibroids affecting approximately 1.4 million women per year. In addition, nearly 60% of women report that symptoms impede physical activity and affect their quality of life. Moreover, 24% of women reported that symptoms prevent them from performing to their full ability at work.

Therefore, the rising demand for novel drugs with an advanced mechanism of action, higher clinical efficacy & lesser side effects is expected to drive the market. In addition, rising funding for research activities is expected to boost market growth. For instance, the Society for Women’s Health Research (SWHR) endorsed the updated & re-introduced Stephanie Tubbs Jones Uterine Fibroid Research & Education Act of 2021. The act is designed to advance funding for research and enhance education regarding the condition. The recent approval of multiple Gonadotropin-releasing Hormone (GnRH) antagonists for the treatment of heavy bleeding associated with fibroids will also drive the market. For instance, in May 2020, the U.S. FDA approved Oriahnn for the treatment of uterine fibroids.

It became the first oral medication approved for the treatment of heavy bleeding in pre-menopausal women. The drug has a treatment duration of 24 months and is available at a retail price of USD 1,100 for 56 tablets. Furthermore, key players are focusing on new launches, mergers & acquisitions, expansion, and partnerships for gaining higher market shares. For instance, in June 2022, Kissei Pharmaceuticals announced the initiation of Phase III trials for its drug, linzagolix, for the treatment of uterine fibroids, in Japan. The drug has already been approved by EMA under the brand name Yselty in Europe. The original developer, ObsEva, sold the regional rights for this drug to Theramex in Feb 2022. The deal grants Theramex the rights to sell this drug in Europe, Brazil, and Australia.

Uterine Fibroid Treatment Drugs Market Report Highlights

  • The GnRH antagonists segment is expected to register the fastest growth rate over the forecast period
  • The recent approval of multiple drugs, such as Oriahnn in May 2020 in the U.S., Myfembree in May 2021 in the U.S., and Yselty in June 2022 in Europe, is expected to drive market growth
  • The submucosal fibroids segment held the majority of the share of the UF drugs market in 2022
  • Retail pharmacies dominated the market in 2022 on account of the ease of availability of medications in these pharmacies
  • North America held the largest share of the global market in 2022 due to various factors, such as the presence of major players, the high prevalence of the health condition, and increasing awareness among patients regarding the availability of medications


This product will be delivered within 1-3 business days.

Table of Contents

Chapter 1 Methodology and Scope
1.1 Market Segmentation and Scope
1.1.1 Estimates And Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database
1.3.2 Gvr’s Internal Database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.3.5 Details Of Primary Research
1.4 Information Or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis
1.6.1.1 Approach: Commodity Flow Approach
1.7 Research Assumptions
1.8 List of Secondary Sources
1.9 List of Abbreviations
1.10 Objectives
1.10.1 Objective 1
1.10.2 Objective 2
1.10.3 Objective 3
1.10.4 Objective 4
Chapter 2 Executive Summary
2.1 Market Snapshot
2.2 Segment Snapshot
2.3 Segment Snapshot
2.4 Competitive Landscape Snapshot
Chapter 3 Uterine Fibroid Treatment Drugs Market Variables, Trends, & Scope
3.1 Uterine Fibroid Treatment Drugs Market Lineage Outlook
3.1.1 Parent Market Outlook
3.1.2 Ancillary Market Outlook Market
3.2 Market Dynamics
3.2.1 Market Driver Impact Analysis
3.2.1.1 Rising Prevalence Of Uterine Fibroids
3.2.1.2 Effectiveness Of Novel Drugs In Reducing Heavy Menstrual Bleeding In Women With Uterine Fibroids
3.2.2 Market Restraint Analysis
3.2.2.1 Availability Of Generic Drugs In The Market
3.3 Industry Analysis Tools
3.3.1 Porter’s Analysis
3.3.2 Macroeconomic Analysis
Chapter 4 Uterine Fibroid Treatment Drugs Market - Segment Analysis, by Drug Class, 2018 - 2030 (USD Million)
4.1 Uterine Fibroid Treatment Drugs Market: Drug Class Movement Analysis
4.2 Uterine Fibroid Treatment Drugs Market Estimates & Forecast, by Drug Class (USD Million)
4.2.1 Gonadotropin-Releasing Hormone (Gnrh) Agonists
4.2.2 Gonadotropin-Releasing Hormone (Gnrh) Antagonists
4.2.3 Progestin-Releasing Intrauterine Device (Iud) & Contraceptives
4.2.4 Non-Hormonal Medications
4.2.5 Others
Chapter 5 Uterine Fibroid Treatment Drugs Market - Segment Analysis, By Type, 2018 - 2030 (USD Million)
5.1 Uterine Fibroid Treatment Drugs Market: Type Movement Analysis
5.2 Uterine Fibroid Treatment Drugs Market Estimates & Forecast, By Type(USD Million)
5.2.1 Subserosal Fibroids
5.2.2 Intramural Fibroids
5.2.3 Submucosal Fibroids
5.2.4 Pedunculated Fibroids
Chapter 6 Uterine Fibroid Treatment Drugs Market - Segment Analysis, By End-User, 2018 - 2030 (USD Million)
6.1 Uterine Fibroid Treatment Drugs Market: End-User Movement Analysis
6.2 Uterine Fibroid Treatment Drugs Market Estimates & Forecast, By End-User (USD Million)
6.2.1 Hospital Pharmacies
6.2.1 Retail Pharmacies
6.2.3 Others
Chapter 7 Uterine Fibroid Treatment Drugs Market: Regional Estimates and Trend Analysis, By Treatment, By Type, and By End User
7.1 Uterine Fibroid Treatment Drugs Market: Regional Outlook
7.2 North America
7.2.1 North America Uterine Fibroid Treatment Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.2.2 U.S.
7.2.2.1 Key Country Dynamics
7.2.2.2 U.S. Uterine Fibroid Treatment Drugs Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
7.2.2.3 Target Disease Incidence
7.2.2.5 Competitive Scenario
7.2.2.6 Regulatory Framework
7.2.2.7 Reimbursement Scenario
7.2.3 Canada
7.2.3.1 Key Country Dynamics
7.2.3.2 Canada Uterine Fibroid Treatment Drugs Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
7.2.3.3 Target Disease Incidence
7.2.3.4 Competitive Scenario
7.2.3.5 Regulatory Framework
7.2.3.6 Reimbursement Scenario
7.3 Europe
7.3.1 Europe Uterine Fibroid Treatment Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.3.2 Uk
7.3.2.1 Key Country Dynamics
7.3.2.2 Uk Uterine Fibroid Treatment Drugs Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
7.3.2.3 Target Disease Incidence
7.3.2.4 Competitive Scenario
7.3.2.5 Regulatory Framework
7.3.2.6 Reimbursement Scenario
7.3.3 Germany
7.3.3.1 Key Country Dynamics
7.3.3.2 Germany Uterine Fibroid Treatment Drugs Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
7.3.3.3 Target Disease Incidence
7.3.3.4 Competitive Scenario
7.3.3.5 Regulatory Framework
7.3.3.6 Reimbursement Scenario
7.3.4 France
7.3.4.1 Key Country Dynamics
7.3.4.2 France Uterine Fibroid Treatment Drugs Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
7.3.4.3 Target Disease Incidence
7.3.4.4 Competitive Scenario
7.3.4.5 Regulatory Framework
7.3.4.6 Reimbursement Scenario
7.3.5 Italy
7.3.5.1 Key Country Dynamics
7.3.5.2 Italy Uterine Fibroid Treatment Drugs Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
7.3.5.3 Target Disease Incidence
7.3.5.4 Competitive Scenario
7.3.5.5 Regulatory Framework
7.3.5.6 Reimbursement Scenario
7.3.6 Spain
7.3.6.1 Key Country Dynamics
7.3.6.2 Spain Uterine Fibroid Treatment Drugs Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
7.3.6.3 Target Disease Incidence
7.3.6.4 Competitive Scenario
7.3.6.5 Regulatory Framework
7.3.6.6 Reimbursement Scenario
7.3.7 Denmark
7.3.7.1 Key Country Dynamics
7.3.7.2 Denmark Uterine Fibroid Treatment Drugs Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
7.3.7.3 Target Disease Incidence
7.3.7.4 Competitive Scenario
7.3.7.5 Regulatory Framework
7.3.7.6 Reimbursement Scenario
7.3.8 Sweden
7.3.8.1 Key Country Dynamics
7.3.8.2 Sweden Uterine Fibroid Treatment Drugs Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
7.3.8.3 Target Disease Incidence
7.3.8.4 Competitive Scenario
7.3.8.5 Regulatory Framework
7.3.8.6 Reimbursement Scenario
7.3.9 Norway
7.3.9.1 Key Country Dynamics
7.3.9.2 Norway Uterine Fibroid Treatment Drugs Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
7.3.9.3 Target Disease Incidence
7.3.9.4 Competitive Scenario
7.3.9.5 Regulatory Framework
7.3.9.6 Reimbursement Scenario
7.4 Asia Pacific
7.4.1 Asia Pacific Uterine Fibroid Treatment Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.4.2 Japan
7.4.2.1 Key Country Dynamics
7.4.2.2 Japan Uterine Fibroid Treatment Drugs Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
7.4.2.3 Target Disease Incidence
7.4.2.4 Competitive Scenario
7.4.2.5 Regulatory Framework
7.4.2.6 Reimbursement Scenario
7.4.3 China
7.4.3.1 Key Country Dynamics
7.4.3.2 China Uterine Fibroid Treatment Drugs Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
7.4.3.3 Target Disease Incidence
7.4.3.4 Competitive Scenario
7.4.3.5 Regulatory Framework
7.4.3.6 Reimbursement Scenario
7.4.4 India
7.4.4.1 Key Country Dynamics
7.4.4.2 India Uterine Fibroid Treatment Drugs Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
7.4.4.3 Target Disease Incidence
7.4.4.4 Competitive Scenario
7.4.4.5 Regulatory Framework
7.4.4.6 Reimbursement Scenario
7.4.5 Australia
7.4.5.1 Key Country Dynamics
7.4.5.2 Australia Uterine Fibroid Treatment Drugs Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
7.4.5.3 Target Disease Incidence
7.4.5.4 Competitive Scenario
7.4.5.5 Regulatory Framework
7.4.5.6 Reimbursement Scenario
7.4.6 South Korea
7.4.6.1 Key Country Dynamics
7.4.6.2 South Korea Uterine Fibroid Treatment Drugs Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
7.4.6.3 Target Disease Incidence
7.4.6.4 Competitive Scenario
7.4.6.5 Regulatory Framework
7.4.6.6 Reimbursement Scenario
7.4.7 Thailand
7.4.7.1 Key Country Dynamics
7.4.7.2 Thailand Uterine Fibroid Treatment Drugs Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
7.4.7.3 Target Disease Incidence
7.4.7.4 Competitive Scenario
7.4.7.5 Regulatory Framework
7.4.7.6 Reimbursement Scenario
7.5 Latin America
7.5.1 Latin America Uterine Fibroid Treatment Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.5.2 Brazil
7.5.2.1 Key Country Dynamics
7.5.2.2 Brazil Uterine Fibroid Treatment Drugs Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
7.5.2.3 Target Disease Incidence
7.5.2.4 Competitive Scenario
7.5.2.5 Regulatory Framework
7.5.2.6 Reimbursement Scenario
7.5.3 Mexico
7.5.3.1 Key Country Dynamics
7.5.3.2 Mexico Uterine Fibroid Treatment Drugs Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
7.5.3.3 Target Disease Incidence
7.5.3.4 Competitive Scenario
7.5.3.5 Regulatory Framework
7.5.3.6 Reimbursement Scenario
7.5.4 Argentina
7.5.4.1 Key Country Dynamics
7.5.4.2 Argentina Uterine Fibroid Treatment Drugs Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
7.5.4.3 Target Disease Incidence
7.5.4.4 Competitive Scenario
7.5.4.5 Regulatory Framework
7.5.4.6 Reimbursement Scenario
7.6 Middle East And Africa
7.6.1 Middle East And Africa Uterine Fibroid Treatment Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.6.1.1 Target Disease Incidence
7.6.1.2 Competitive Scenario
7.6.1.3 Regulatory Framework
7.6.1.4 Reimbursement Scenario
7.6.2 South Africa
7.6.2.1 Key Country Dynamics
7.6.2.2 South Africa Uterine Fibroid Treatment Drugs Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
7.6.2.3 Target Disease Incidence
7.6.2.4 Competitive Scenario
7.6.2.5 Regulatory Framework
7.6.2.6 Reimbursement Scenario
7.6.3 Saudi Arabia
7.6.3.1 Key Country Dynamics
7.6.3.2 Saudi Arabia Uterine Fibroid Treatment Drugs Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
7.6.3.3 Target Disease Incidence
7.6.3.4 Competitive Scenario
7.6.3.5 Regulatory Framework
7.6.3.6 Reimbursement Scenario
7.6.4 UAE
7.6.4.1 Key Country Dynamics
7.6.4.2 UAE Uterine Fibroid Treatment Drugs Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
7.6.4.3 Target Disease Incidence
7.6.4.4 Competitive Scenario
7.6.4.5 Regulatory Framework
7.6.4.6 Reimbursement Scenario
7.6.5 Kuwait
7.6.5.1 Key Country Dynamics
7.6.5.2 Kuwait Uterine Fibroid Treatment Drugs Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
7.6.5.3 Target Disease Incidence
7.6.5.4 Competitive Scenario
7.6.5.5 Regulatory Framework
7.6.5.6 Reimbursement Scenario
Chapter 8 Competitive Landscape
8.1 Company Market Positioning
8.2 Company Market Share Analysis, 2022
8.3 Company Heat Map Analysis
8.4 Company Profiles
8.4.1 Myovant Sciences Gmbh
8.4.1.1 Company Overview
8.4.1.2 Financial Performance
8.4.1.3 Product Benchmarking
8.4.1.4 Strategic Initiatives
8.4.2 Pfizer Inc.
8.4.2.1 Company Overview
8.4.2.2 Financial Performance
8.4.2.3 Product Benchmarking
8.4.2.4 Strategic Initiatives
8.4.3 Abbvie, Inc.
8.4.3.1 Company Overview
8.4.3.2 Financial Performance
8.4.3.3 Product Benchmarking
8.4.3.4 Strategic Initiatives
8.4.4 Ferring B.V.
8.4.4.1 Company Overview
8.4.4.2 Financial Performance
8.4.4.3 Product Benchmarking
8.4.4.4 Strategic Initiatives
8.4.5 Astrazeneca
8.4.5.1 Company Overview
8.4.5.2 Financial Performance
8.4.5.3 Product Benchmarking
8.4.5.4 Strategic Initiatives
8.4.6 Bayer Ag
8.4.6.1 Company Overview
8.4.6.2 Financial Performance
8.4.6.3 Product Benchmarking
8.4.6.4 Strategic Initiatives
8.4.7 Amring Pharmaceuticals Inc.
8.4.7.1 Company Overview
8.4.7.2 Financial Performance
8.4.7.3 Product Benchmarking
8.4.7.4 Strategic Initiatives
8.4.8 Watson Pharma, Inc.
8.4.8.1 Company overview
8.4.8.2 Financial performance
8.4.8.3 Product benchmarking
8.4.8.4 Strategic initiatives
List of Tables
Table 1 List of Secondary Sources
Table 2 List of Abbreviation
Table 3 Incidence of Diseases
Table 4 Global Uterine Fibroid Treatment Drugs Market, By Region, 2018 - 2030 (USD Million)
Table 5 North America Uterine Fibroid Treatment Drugs Market, By Country, 2018 - 2030 (USD Million)
Table 6 North America Uterine Fibroid Treatment Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 7 North America Uterine Fibroid Treatment Drugs Market, By Type, 2018 - 2030 (USD Million)
Table 8 North America Uterine Fibroid Treatment Drugs Market, By End-User, 2018 - 2030 (USD Million)
Table 9 U.S. Uterine Fibroid Treatment Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 10 U.S. Uterine Fibroid Treatment Drugs Market, By Type, 2018 - 2030 (USD Million)
Table 11 U.S. Uterine Fibroid Treatment Drugs Market, By End-User, 2018 - 2030 (USD Million)
Table 12 Canada Uterine Fibroid Treatment Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 13 Canada Uterine Fibroid Treatment Drugs Market, By Type, 2018 - 2030 (USD Million)
Table 14 Canada Uterine Fibroid Treatment Drugs Market, By End-User, 2018 - 2030 (USD Million)
Table 15 Europe Uterine Fibroid Treatment Drugs Market, By Country, 2018 - 2030 (USD Million)
Table 16 Europe Uterine Fibroid Treatment Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 17 Europe Uterine Fibroid Treatment Drugs Market, By Type, 2018 - 2030 (USD Million)
Table 18 Europe Uterine Fibroid Treatment Drugs Market, By End-User, 2018 - 2030 (USD Million)
Table 19 UK Uterine Fibroid Treatment Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 20 UK Uterine Fibroid Treatment Drugs Market, By Type, 2018 - 2030 (USD Million)
Table 21 UK Uterine Fibroid Treatment Drugs Market, By End-User, 2018 - 2030 (USD Million)
Table 22 Germany Uterine Fibroid Treatment Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 23 Germany Uterine Fibroid Treatment Drugs Market, By Type, 2018 - 2030 (USD Million)
Table 24 Germany Uterine Fibroid Treatment Drugs Market, By End-User, 2018 - 2030 (USD Million)
Table 25 France Uterine Fibroid Treatment Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 26 France Uterine Fibroid Treatment Drugs Market, By Type, 2018 - 2030 (USD Million)
Table 27 France Uterine Fibroid Treatment Drugs Market, By End-User, 2018 - 2030 (USD Million)
Table 28 Italy Uterine Fibroid Treatment Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 29 Italy Uterine Fibroid Treatment Drugs Market, By Type, 2018 - 2030 (USD Million)
Table 30 Italy Uterine Fibroid Treatment Drugs Market, By End-User, 2018 - 2030 (USD Million)
Table 31 Spain Uterine Fibroid Treatment Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 32 Spain Uterine Fibroid Treatment Drugs Market, By Type, 2018 - 2030 (USD Million)
Table 33 Spain Uterine Fibroid Treatment Drugs Market, By End-User, 2018 - 2030 (USD Million)
Table 34 Denmark Uterine Fibroid Treatment Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 35 Denmark Uterine Fibroid Treatment Drugs Market, By Type, 2018 - 2030 (USD Million)
Table 36 Denmark Uterine Fibroid Treatment Drugs Market, By End-User, 2018 - 2030 (USD Million)
Table 37 Sweden Uterine Fibroid Treatment Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 38 Sweden Uterine Fibroid Treatment Drugs Market, By Type, 2018 - 2030 (USD Million)
Table 39 Sweden Uterine Fibroid Treatment Drugs Market, By End-User, 2018 - 2030 (USD Million)
Table 40 Norway Uterine Fibroid Treatment Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 41 Norway Uterine Fibroid Treatment Drugs Market, By Type, 2018 - 2030 (USD Million)
Table 42 Norway Uterine Fibroid Treatment Drugs Market, By End-User, 2018 - 2030 (USD Million)
Table 43 Asia Pacific Uterine Fibroid Treatment Drugs Market, By Country, 2018 - 2030 (USD Million)
Table 44 Asia Pacific Uterine Fibroid Treatment Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 45 Asia Pacific Uterine Fibroid Treatment Drugs Market, By Type, 2018 - 2030 (USD Million)
Table 46 Asia Pacific Uterine Fibroid Treatment Drugs Market, By End-User, 2018 - 2030 (USD Million)
Table 47 Japan Uterine Fibroid Treatment Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 48 Japan Uterine Fibroid Treatment Drugs Market, By Type, 2018 - 2030 (USD Million)
Table 49 Japan Uterine Fibroid Treatment Drugs Market, By End-User, 2018 - 2030 (USD Million)
Table 50 China Uterine Fibroid Treatment Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 51 China Uterine Fibroid Treatment Drugs Market, By Type, 2018 - 2030 (USD Million)
Table 52 China Uterine Fibroid Treatment Drugs Market, By End-User, 2018 - 2030 (USD Million)
Table 53 India Uterine Fibroid Treatment Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 54 India Uterine Fibroid Treatment Drugs Market, By Type, 2018 - 2030 (USD Million)
Table 55 India Uterine Fibroid Treatment Drugs Market, By End-User, 2018 - 2030 (USD Million)
Table 56 Australia Uterine Fibroid Treatment Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 57 Australia Uterine Fibroid Treatment Drugs Market, By Type, 2018 - 2030 (USD Million)
Table 58 Australia Uterine Fibroid Treatment Drugs Market, By End-User, 2018 - 2030 (USD Million)
Table 59 South Korea Uterine Fibroid Treatment Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 60 South Korea Uterine Fibroid Treatment Drugs Market, By Type, 2018 - 2030 (USD Million)
Table 61 South Korea Uterine Fibroid Treatment Drugs Market, By End-User, 2018 - 2030 (USD Million)
Table 62 Thailand Uterine Fibroid Treatment Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 63 Thailand Uterine Fibroid Treatment Drugs Market, By Type, 2018 - 2030 (USD Million)
Table 64 Thailand Uterine Fibroid Treatment Drugs Market, By End-User, 2018 - 2030 (USD Million)
Table 65 Latin America Uterine Fibroid Treatment Drugs Market, By Country, 2018 - 2030 (USD Million)
Table 66 Latin America Uterine Fibroid Treatment Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 67 Latin America Uterine Fibroid Treatment Drugs Market, By Type, 2018 - 2030 (USD Million)
Table 68 Latin America Uterine Fibroid Treatment Drugs Market, By End-User, 2018 - 2030 (USD Million)
Table 69 Brazil Uterine Fibroid Treatment Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 70 Brazil Uterine Fibroid Treatment Drugs Market, By Type, 2018 - 2030 (USD Million)
Table 71 Brazil Uterine Fibroid Treatment Drugs Market, By End-User, 2018 - 2030 (USD Million)
Table 72 Mexico Uterine Fibroid Treatment Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 73 Mexico Uterine Fibroid Treatment Drugs Market, By Type, 2018 - 2030 (USD Million)
Table 74 Mexico Uterine Fibroid Treatment Drugs Market, By End-User, 2018 - 2030 (USD Million)
Table 75 Argentina Uterine Fibroid Treatment Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 76 Argentina Uterine Fibroid Treatment Drugs Market, By Type, 2018 - 2030 (USD Million)
Table 77 Argentina Uterine Fibroid Treatment Drugs Market, By End-User, 2018 - 2030 (USD Million)
Table 78 Middle East & Africa Uterine Fibroid Treatment Drugs Market, By Country, 2018 - 2030 (USD Million)
Table 79 Middle East & Africa Uterine Fibroid Treatment Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 80 Middle East & Africa Uterine Fibroid Treatment Drugs Market, By Type, 2018 - 2030 (USD Million)
Table 81 Middle East & Africa Uterine Fibroid Treatment Drugs Market, By End-User, 2018 - 2030 (USD Million)
Table 82 South Africa Uterine Fibroid Treatment Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 83 South Africa Uterine Fibroid Treatment Drugs Market, By Type, 2018 - 2030 (USD Million)
Table 84 South Africa Uterine Fibroid Treatment Drugs Market, By End-User, 2018 - 2030 (USD Million)
Table 85 Saudi Arabia Uterine Fibroid Treatment Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 86 Saudi Arabia Uterine Fibroid Treatment Drugs Market, By Type, 2018 - 2030 (USD Million)
Table 87 Saudi Arabia Uterine Fibroid Treatment Drugs Market, By End-User, 2018 - 2030 (USD Million)
Table 88 UAE Uterine Fibroid Treatment Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 89 UAE Uterine Fibroid Treatment Drugs Market, By Type, 2018 - 2030 (USD Million)
Table 90 UAE Uterine Fibroid Treatment Drugs Market, By End-User, 2018 - 2030 (USD Million)
Table 91 Kuwait Uterine Fibroid Treatment Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 92 Kuwait Uterine Fibroid Treatment Drugs Market, By Type, 2018 - 2030 (USD Million)
Table 93 Kuwait Uterine Fibroid Treatment Drugs Market, By End-User, 2018 - 2030 (USD Million)
List of Figures
Fig. 1 Market Research Process
Fig. 2 Information Procurement
Fig. 3 Primary Research Pattern
Fig. 4 Market Research Approaches
Fig. 5 Value Chain-Based Sizing & Forecasting
Fig. 6 Market Formulation & Validation
Fig. 7 Uterine Fibroid Treatment Drugs Market Segmentation
Fig. 8 Market Driver Relevance Analysis (Current & Future Impact)
Fig. 9 Market Restraint Relevance Analysis (Current & Future Impact)
Fig. 10 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
Fig. 11 Porter’s Five Forces Analysis
Fig. 12 Pipeline Analysis
Fig. 13 Uterine fibroid treatment drugs market: Drug class outlook and key takeaways
Fig. 14 Uterine fibroid treatment drugs market: Drug class movement analysis & market share 2022 & 2030
Fig. 15 Gonadotropin-releasing hormone (GnRH) agonists market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 16 Gonadotropin-releasing hormone (GnRH) antagonists market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 17 Progestin-releasing intrauterine device (IUD) & contraceptives market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 18 Non-hormonal medications market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 19 Others market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 20 Uterine fibroid treatment drugs market: Type outlook and key takeaways
Fig. 21 Uterine fibroid treatment drugs market: Type movement analysis & market share 2022 & 2030
Fig. 22 Subserosal fibroids market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 23 Intramural fibroids market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 24 Submucosal fibroids market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 25 Pedunculated fibroids market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 26 Uterine fibroid treatment drugs market: End-User outlook and key takeaways
Fig. 27 Uterine fibroid treatment drugs market: End-User movement analysis & market share 2022 & 2030
Fig. 28 Hospital pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 29 Retail pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 30 Others market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 31 Regional Marketplace: Key Takeaways
Fig. 32 Regional Outlook, 2022 & 2030
Fig. 33 Regional Market Dashboard
Fig. 34 Regional Market Place: Key Takeaways
Fig. 35 North America
Fig. 36 North America Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 37 U.S.
Fig. 38 U.S. Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 39 Canada
Fig. 40 Canada Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 41 Europe
Fig. 42 Europe Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 43 UK
Fig. 44 UK Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 45 Germany
Fig. 46 Germany Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 47 France
Fig. 48 France Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 49 Italy
Fig. 50 Italy Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 51 Spain
Fig. 52 Spain Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 53 Denmark
Fig. 54 Denmark Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 55 Sweden
Fig. 56 Sweden Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 57 Norway
Fig. 58 Norway Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 59 Asia Pacific
Fig. 60 Asia-Pacific Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 61 Japan
Fig. 62 Japan Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 63 China
Fig. 64 China Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 65 India
Fig. 66 India Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 67 Australia
Fig. 68 Australia Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 69 South Korea
Fig. 70 South Korea Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 71 Thailand
Fig. 72 Thailand Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 73 Latin America
Fig. 74 Latin America Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 75 Brazil
Fig. 76 Brazil Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 77 Mexico
Fig. 78 Mexico Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 79 Argentina
Fig. 80 Argentina Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 81 MEA
Fig. 82 MEA Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 83 South Africa
Fig. 84 South Africa Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 85 Saudi Arabia
Fig. 86 Saudi Arabia Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 87 UAE
Fig. 88 UAE Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 89 Kuwait
Fig. 90 Kuwait Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 91 Strategy Mapping

Companies Mentioned

  • Myovant Sciences Gmbh
  • Pfizer Inc.
  • Abbvie, Inc.
  • Ferring B.V.
  • Astrazeneca
  • Bayer Ag
  • Amring Pharmaceuticals Inc.
  • Watson Pharma, Inc.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages130
PublishedMay 2023
Forecast Period2022 - 2030
Estimated Market Value ( USD ) in 2022 $ 1.8 Billion
Forecasted Market Value ( USD ) by 2030 $ 3.91 Billion
Compound Annual Growth Rate10.2%
Regions CoveredGlobal
No. of Companies Mentioned8

Related Topics

Related Reports

Uterine Fibroid Treatment Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F - Product Image

Uterine Fibroid Treatment Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F

  • Report
  • 171 Pages
  • Global
From
Global Uterine Fibroid Treatment Device Market by Technology (Ablation Techniques, Embolization Techniques, Laparoscopic Techniques), Mode of Treatment (Invasive Treatment, Minimally Invasive Treatment, Non-Invasive Treatment) - Forecast 2024-2030 - Product Image

Global Uterine Fibroid Treatment Device Market by Technology (Ablation Techniques, Embolization Techniques, Laparoscopic Techniques), Mode of Treatment (Invasive Treatment, Minimally Invasive Treatment, Non-Invasive Treatment) - Forecast 2024-2030

  • Report
  • 197 Pages
  • Global
From
Uterine Fibroids Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F - Product Image

Uterine Fibroids Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F

  • Report
  • 182 Pages
  • Global
From
Uterine fibroids - Pipeline Insight, 2024 - Product Image

Uterine fibroids - Pipeline Insight, 2024

  • Clinical Trials
  • 60 Pages
  • Global
From
Uterine Leiomyoma (Uterine Fibroids) - Pipeline Insight, 2024 - Product Image

Uterine Leiomyoma (Uterine Fibroids) - Pipeline Insight, 2024

  • Clinical Trials
  • 70 Pages
  • Global
From

About the Uterine Fibroids Drug Market

Uterine Fibroids Drug market is a segment of the Women's Health industry that focuses on the treatment of uterine fibroids. Uterine fibroids are non-cancerous growths that can cause heavy menstrual bleeding, pelvic pain, and other symptoms. Treatment options include medications, minimally invasive procedures, and surgery. Medications used to treat uterine fibroids include gonadotropin-releasing hormone agonists, progestins, androgens, and selective progesterone receptor modulators. Minimally invasive procedures include uterine artery embolization, endometrial ablation, and myolysis. Surgery is the most invasive option and includes hysterectomy and myomectomy. Companies in the Uterine Fibroids Drug market include AbbVie, Bayer, Pfizer, Allergan, and Merck. Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.